View Exam | PowerPak

1. Based on the claims data reviewed, which of the following patients has the highest likelihood for PCSK9 inhibitor approval and patient pick-up from the pharmacy?

A. A 26-year-old male with newly diagnosed FH on no drug therapy B. A 45-year-old female with clinical ASCVD on atorvastatin and ezetimibe, managed by her cardiologist C. A 64-year-old male with clinical ASCVD prescribed a PCSK9 inhibitor by his family doctor D. A 66-year-old female with FH and a PCSK9 inhibitor copay of $560

2. All of the following are established adverse effects of PCSK9 inhibitors, EXCEPT:

A. Dementia B. Nasopharyngitis C. Injection site reactions D. Musculoskeletal pain

3. Claims data revealed which of the following is associated with the highest likelihood of PCSK9 inhibitor approval?

A. High LDL-C levels B. High-intensity statin use C. Use of a specialty pharmacy D. Prescription generation from a lipid specialist

4. Specialty pharmacies can assist in which of the following activities related to PCSK9 inhibitor therapy?

A. Adherence education B. Prior authorization processes C. Identification of appropriate patients D. All of the above

5. According to the 2017 NLA survey, which of the following was cited as the greatest barrier to providers prescribing PCSK9 inhibitors despite access to prior authorization resources?

A. Medication cost B. Patient adherence C. Unclear patient selection criteria D. Comfort with PCSK9 inhibitors

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Based on the claims data reviewed, which of the following patients has the highest likelihood for PCSK9 inhibitor approval and patient pick-up from the pharmacy?

2. All of the following are established adverse effects of PCSK9 inhibitors, EXCEPT:

3. Claims data revealed which of the following is associated with the highest likelihood of PCSK9 inhibitor approval?

4. Specialty pharmacies can assist in which of the following activities related to PCSK9 inhibitor therapy?

5. According to the 2017 NLA survey, which of the following was cited as the greatest barrier to providers prescribing PCSK9 inhibitors despite access to prior authorization resources?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Based on the claims data reviewed, which of the following patients has the highest likelihood for PCSK9 inhibitor approval and patient pick-up from the pharmacy?

2. All of the following are established adverse effects of PCSK9 inhibitors, EXCEPT:

3. Claims data revealed which of the following is associated with the highest likelihood of PCSK9 inhibitor approval?

4. Specialty pharmacies can assist in which of the following activities related to PCSK9 inhibitor therapy?

5. According to the 2017 NLA survey, which of the following was cited as the greatest barrier to providers prescribing PCSK9 inhibitors despite access to prior authorization resources?

« Return to Activity

Customers who Purchased
this Activity also Purchased